Amylx Pharmaceuticals Inc vs Figs Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.72 (market cap $2.64B), while Figs Inc trades at $14.12 (market cap $2.37B). The key difference: Amylx Pharmaceuticals Inc and Figs Inc are close in size by market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Figs Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | FIGS | |
|---|---|---|
Market Cap | $2.64B | $2.37B |
Sector | Health | Consumer Cyclical |
52-Week High | $24.19 | $17.12 |
52-Week Low | $7.82 | $6.57 |
Enterprise Value | $2.39B | $2.13B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
FIGS stock trades at $14.39, up 0.91% today, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with 28.8% revenue growth, and raised its full-year outlook. Valuation remains elevated with a P/E of 43.24 and P/S of 3.83, while profitability improved with a net income margin of 8.72% in 2025.
The outlook is positive given accelerating revenue growth and margin expansion, but the rich valuation poses a risk if execution falters. Analyst consensus is bullish with a $19.50 price target, though high RSI readings suggest near-term overbought conditions. Key risks include second-half execution challenges and competitive pressures in healthcare apparel.
Trailing returns across standard periods
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →